Laura B. Goddard

Array ( [id] => 18583147 [patent_doc_number] => 20230265406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/003234 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18150576 [patent_doc_number] => 20230024434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles [patent_app_type] => utility [patent_app_number] => 17/358186 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675157 [patent_doc_number] => 20230312744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same [patent_app_type] => utility [patent_app_number] => 18/022593 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314905 [patent_doc_number] => 20210403953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => TARGETED INTEGRATION OF NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/351451 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18872371 [patent_doc_number] => 11860165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => CORE3-MUC1 binding polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 17/351596 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 71 [patent_figures_cnt] => 116 [patent_no_of_words] => 47223 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529990 [patent_doc_number] => 20230235058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => BTLA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/001367 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497451 [patent_doc_number] => 20230220087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies [patent_app_type] => utility [patent_app_number] => 18/001025 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17521473 [patent_doc_number] => 20220107322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/343538 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497451 [patent_doc_number] => 20230220087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies [patent_app_type] => utility [patent_app_number] => 18/001025 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156450 [patent_doc_number] => 20210317501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS [patent_app_type] => utility [patent_app_number] => 17/342244 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156450 [patent_doc_number] => 20210317501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS OF PRODUCING POLYPEPTIDES USING A CELL LINE RESISTANT TO APOPTOSIS [patent_app_type] => utility [patent_app_number] => 17/342244 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434427 [patent_doc_number] => 20230181721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => VACCINE AGAINST SARS-COV VIRUS [patent_app_type] => utility [patent_app_number] => 17/924371 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505212 [patent_doc_number] => 20220098314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/316141 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036699 [patent_doc_number] => 20210253657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TUMOR-PENETRATING PEPTIDE AND ANTIANGIOGENESIS AGENT ARE FUSED, FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/306315 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434311 [patent_doc_number] => 20230181605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 17/923189 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434311 [patent_doc_number] => 20230181605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 17/923189 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18359277 [patent_doc_number] => 20230140868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/995800 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156171 [patent_doc_number] => 20210317222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => IMMUNOMODULATORY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/235174 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156171 [patent_doc_number] => 20210317222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => IMMUNOMODULATORY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/235174 [patent_app_country] => US [patent_app_date] => 2021-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987788 [patent_doc_number] => 20240059757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/996209 [patent_app_country] => US [patent_app_date] => 2021-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996209 [rel_patent_id] =>[rel_patent_doc_number] =>)